ALX Oncology Holdings Inc. (ALXO)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGS
2.00 USD
+0.03
(1.523%)
⇧
(July 14, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 6:13 a.m. EDT
The investment case here is severely compromised by a catastrophic multi-year price collapse. Despite the company adding a secured loan facility and being added to an index, the stock has lost over 98% of its value since 2020, driven by a brutal -93.77% drop last year. While the balance sheet currently looks robust with a current ratio of 7.2 and manageable debt relative to cash, the market has clearly priced in a fundamental deterioration that has erased nearly all equity value. The negative free cash flow and losses suggest the business is still burning capital without generating returns. On the short end, the recent price action shows a modest bounce off lows, but the lack of meaningful options activity and the 'very low' confidence in statistical forecasts mean there is no clear momentum edge to exploit. This is a deep value trap where the price has fallen so far that the remaining equity is likely insufficient to cover the massive operational risks ahead. |
| Model | MAE |
|---|---|
| MSTL_74 ✓ | 0.114699 |
| MSTL_74_115 | 0.151017 |
| AutoETS | 0.184354 |
| MSTL | 0.187670 |
| AutoARIMA | 0.191204 |
| AutoTheta | 0.198834 |
| MSTL_115 | 0.273070 |
Forecast horizon: 60 days | Selected: MSTL_74
| Forecast Reliability | |
|---|---|
| Score | 29% |
| H-stat | 4.23 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.318 |
| Excess Kurtosis | -0.89 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 8.621 |
| Market Cap | 269,125,824 |
| Forward P/E | -3.72 |
| Beta | 0.43 |
| Website | https://www.alxoncology.com |
As of July 11, 2026, 6:13 a.m. EDT: Speculator positioning is extremely thin and fragmented. In the near term (July/August 2026), there is negligible open interest or volume for either calls or puts, suggesting a lack of active directional bets. The only notable concentration appears in January 2027 calls, where significant open interest sits at strikes below the current price ($1.50 and $2.00), indicating some hedging or speculative insurance against further downside rather than a bullish breakout thesis. Put activity remains sparse across all expirations.
| Attribute | Value |
|---|---|
| 52 Week Change | 3.2184153 |
| Address1 | 323 Allerton Avenue |
| All Time High | 117.45 |
| All Time Low | 0.404 |
| Ask | 2.45 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 1,324,020 |
| Average Daily Volume3 Month | 1,408,014 |
| Average Volume | 1,408,014 |
| Average Volume10Days | 1,324,020 |
| Beta | 0.432 |
| Bid | 1.44 |
| Bid Size | 2 |
| Book Value | 1.125 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.0 |
| Current Ratio | 7.214 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 2.02 |
| Day Low | 1.91 |
| Debt To Equity | 8.621 |
| Display Name | ALX Oncology |
| Earnings Call Timestamp End | 1,778,243,400 |
| Earnings Call Timestamp Start | 1,778,243,400 |
| Earnings Timestamp | 1,778,243,400 |
| Earnings Timestamp End | 1,778,243,400 |
| Earnings Timestamp Start | 1,778,243,400 |
| Ebitda | -87,347,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.624 |
| Enterprise Value | 141,849,840 |
| Eps Current Year | -0.64934 |
| Eps Forward | -0.53804 |
| Eps Trailing Twelve Months | -1.49 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.8693 |
| Fifty Day Average Change | 0.13069999 |
| Fifty Day Average Change Percent | 0.06991921 |
| Fifty Two Week Change Percent | 321.84152 |
| Fifty Two Week High | 2.66 |
| Fifty Two Week High Change | -0.6600001 |
| Fifty Two Week High Change Percent | -0.24812032 |
| Fifty Two Week Low | 0.444 |
| Fifty Two Week Low Change | 1.556 |
| Fifty Two Week Low Change Percent | 3.5045044 |
| Fifty Two Week Range | 0.444 - 2.66 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,594,992,600,000 |
| Float Shares | 64,432,762 |
| Forward Eps | -0.53804 |
| Forward P E | -3.717196 |
| Free Cashflow | -47,769,376 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 43 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0092 |
| Held Percent Institutions | 0.78789 |
| Implied Shares Outstanding | 134,562,917 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California. |
| Long Name | ALX Oncology Holdings Inc. |
| Market | us_market |
| Market Cap | 269,125,824 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_301925264 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -88,868,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 265,088,946 |
| Number Of Analyst Opinions | 5 |
| Open | 1.99 |
| Operating Cashflow | -78,127,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 650 466 7125 |
| Previous Close | 1.97 |
| Price Eps Current Year | -3.0800507 |
| Price Hint | 4 |
| Price To Book | 1.7777778 |
| Profit Margins | 0.0 |
| Quick Ratio | 7.003 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.029999971 |
| Regular Market Change Percent | 1.5228412 |
| Regular Market Day High | 2.02 |
| Regular Market Day Low | 1.91 |
| Regular Market Day Range | 1.91 - 2.02 |
| Regular Market Open | 1.99 |
| Regular Market Previous Close | 1.97 |
| Regular Market Price | 2.0 |
| Regular Market Time | 1,784,059,201 |
| Regular Market Volume | 767,635 |
| Return On Assets | -0.36758 |
| Return On Equity | -0.74167 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 134,562,917 |
| Shares Percent Shares Out | 0.047 |
| Shares Short | 6,318,290 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 1,705,895 |
| Short Name | ALX Oncology Holdings Inc. |
| Short Percent Of Float | 0.052199997 |
| Short Ratio | 3.18 |
| Source Interval | 15 |
| State | CA |
| Symbol | ALXO |
| Target High Price | 6.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 4.6 |
| Target Median Price | 4.0 |
| Total Cash | 140,324,000 |
| Total Cash Per Share | 1.043 |
| Total Debt | 13,048,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.49 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.750125 |
| Two Hundred Day Average Change | 0.24987495 |
| Two Hundred Day Average Change Percent | 0.14277548 |
| Type Disp | Equity |
| Volume | 767,635 |
| Website | https://www.alxoncology.com |
| Zip | 94,080 |